Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer

BACKGROUND: Many oncological drugs that are being used in the adjuvant setting were first submitted for reimbursement in the metastatic stage, with differences in incremental cost-effectiveness ratios (ICERs) in both settings having potential implications for reimbursement and pricing. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dvortsin, Evgeni, Gout-Zwart, Judith, Eijssen, Ernst-Lodewijk Marie, van Brussel, Jan, Postma, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723090/
https://www.ncbi.nlm.nih.gov/pubmed/26800029
http://dx.doi.org/10.1371/journal.pone.0146551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723090/
https://www.ncbi.nlm.nih.gov/pubmed/26800029
http://dx.doi.org/10.1371/journal.pone.0146551

Ejemplares similares